361 related articles for article (PubMed ID: 27852851)
21. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
22. Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike.
Cai Y; Karaca-Griffin S; Chen J; Tian S; Fredette N; Linton CE; Rits-Volloch S; Lu J; Wagh K; Theiler J; Korber B; Seaman MS; Harrison SC; Carfi A; Chen B
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4477-4482. PubMed ID: 28396421
[TBL] [Abstract][Full Text] [Related]
23. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
24. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
25. Recombinant antibodies with conformationally constrained HIV type 1 epitope inserts elicit glycoprotein 160-specific antibody responses in vivo.
Cook J; Barber BH
AIDS Res Hum Retroviruses; 1997 Apr; 13(6):449-60. PubMed ID: 9100986
[TBL] [Abstract][Full Text] [Related]
26. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
27. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
28. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.
Chong H; Hong K; Zhang C; Nie J; Song A; Kong W; Wang Y
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):535-43. PubMed ID: 18209676
[TBL] [Abstract][Full Text] [Related]
29. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
[TBL] [Abstract][Full Text] [Related]
30. Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs.
Witt KC; Castillo-Menendez L; Ding H; Espy N; Zhang S; Kappes JC; Sodroski J
PLoS One; 2017; 12(2):e0170672. PubMed ID: 28151945
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
D'Souza MP; Livnat D; Bradac JA; Bridges SH
J Infect Dis; 1997 May; 175(5):1056-62. PubMed ID: 9129066
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
[TBL] [Abstract][Full Text] [Related]
34. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
35. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
[TBL] [Abstract][Full Text] [Related]
37. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
Moore PL; Crooks ET; Porter L; Zhu P; Cayanan CS; Grise H; Corcoran P; Zwick MB; Franti M; Morris L; Roux KH; Burton DR; Binley JM
J Virol; 2006 Mar; 80(5):2515-28. PubMed ID: 16474158
[TBL] [Abstract][Full Text] [Related]
38. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
39. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
